Duperray C, Bataille R, Boiron J M, Haagen I A, Cantaloube J F, Zhang X G, Boucheix C, Klein B
INSERM U291, Montpellier, France.
Cancer Res. 1991 Jun 15;51(12):3224-8.
We have recently demonstrated that the CD24 antigen density of bone marrow (BM) lymphoid cells discriminates between pre-B cells and mature B-cells. Using this new method, we evaluated the B-cell lineage in the BM and peripheral blood (PB) of 18 patients with multiple myeloma (MM). First, the percentage of pre-B cells was significantly reduced by 40% in the BM of patients with MM: 2.3% +/- 2.2% versus 5.7% +/- 2.8% of normal BM lymphoid cells (P less than 0.01). This finding was associated with a significant reduction (50%) of the percentage of mature B-cells in both BM and PB, especially in patients with progressive disease (P less than 0.05). In contrast to what has been reported previously, we have not found any pre-B cells in the PB of these patients with MM. Secondly, BM pre-B and B-cell patients with MM did not express any activation markers (CD23, CD25, or CD71 antigens) and no CD5+ B-cells were found in the BM unlike in PB (8% CD5+ B-cells). Taken together, these data do not support the concept of a direct involvement (i.e, expansion or activation) of pre-B cells in MM without excluding the possibility of an early oncogenic event at the pre-B cell stage. Furthermore, our data emphasize this important reduction of the B-cell compartment (including that of pre-B cell) as a major cause of the humoral immunodeficiency in MM.
我们最近证明，骨髓（BM）淋巴样细胞的CD24抗原密度可区分前B细胞和成熟B细胞。利用这种新方法，我们评估了18例多发性骨髓瘤（MM）患者骨髓和外周血（PB）中的B细胞谱系。首先，MM患者骨髓中的前B细胞百分比显著降低了40%：2.3%±2.2%，而正常骨髓淋巴样细胞为5.7%±2.8%（P<0.01）。这一发现与骨髓和外周血中成熟B细胞百分比的显著降低（50%）相关，尤其是在疾病进展的患者中（P<0.05）。与之前报道的情况相反，我们在这些MM患者的外周血中未发现任何前B细胞。其次，MM患者的骨髓前B细胞和B细胞不表达任何激活标志物（CD23、CD25或CD71抗原），且与外周血不同（8%的CD5+B细胞），骨髓中未发现CD5+B细胞。综上所述，这些数据不支持前B细胞直接参与MM（即扩增或激活）的概念，但不排除在前B细胞阶段发生早期致癌事件的可能性。此外，我们的数据强调了B细胞区室（包括前B细胞区室）的这种重要减少是MM体液免疫缺陷的主要原因。
